TESLAC
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jun 1969
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TESLAC is an injectable small-molecule product approved by Bristol Myers Squibb in 1969. The specific indication and mechanism of action are not publicly documented in available data. This legacy product represents a historical asset in the BMS portfolio.
LOE Approaching
With LOE approaching and minimal current spending data, commercial team size is likely small and focused on managed decline or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and LOE approaching, TESLAC offers limited career momentum opportunities. Roles on this product focus on defending market share, managing decline, and ensuring smooth transition post-LOE.
Brand ManagerProduct Manager
Worked on TESLAC at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.